Tamsulosin OCAS is one of 15 small molecule programs targeting Dysuria. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
14 competitors in Urinary Retention
Flomax
Robinul
Bridion
Avodart
Esmeron
Ivadantin
Tamsulosin OCAS
No Intrathecal Morphine
Minipress
Decadron
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources